Retatrutide
In clinical trialsAlso known as: LY3437943, "Reta"
Category: Weight & metabolic
Sold as:
Ameano Peptides: AMP-3P
Nexaph: NXP-3P
Investigational triple agonist of GLP-1, GIP and glucagon receptors. Phase 2 trials showed very large weight loss.
What it's used for
- Obesity (investigational)
- Type 2 diabetes (investigational)
- Fatty liver disease (investigational)
Dosing
- Typical dose
- Trial protocols started at 2 mg weekly and escalated every 4 weeks toward 8 to 12 mg weekly. No approved dose exists.
- How often
- Once weekly
- Route
- Subcutaneous injection
- Cycle length
- Trial durations were 48 weeks or longer
Build a dosing plan for Retatrutide →
How to reconstitute and measure a dose → · About bacteriostatic water →
Possible side effects
- GI side effects similar to other incretin drugs
- Increased heart rate at higher doses
Important: Not approved. Anything sold outside clinical trials is unregulated and purity cannot be assumed.
Also sold in blends
- Reta/Cagri Blend: Retatrutide 12.5 mg + Cagrilintide 2.5 mg (Ameano Peptides)